Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Allen Morey

Urology Dallas, TX Medical Doctor

NPI 1972578755 CMS profile 135008

5323 Harry Hines Blvd, Dallas, TX 75390

Open in the dashboard

General payments

$913,827

1,268 records reported · program years 2019–2025

Research payments

$5,030

Paid to them · 1 record reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$92,742 paid to institutions, not to them · program years 2022–2025

Through program year 2025, Allen Morey of Dallas, TX is reported in the CMS Open Payments database as having received $913,827 across 1,268 general payments and $5,030 in research payments paid to them. Separately, studies naming them as principal investigator received $92,742 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 99th percentile of Urology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

8 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $211,651 220
2024 General $217,748 222
2024 Research $5,030 1
2023 General $140,373 152
2022 General $111,304 190
2021 General $89,824 159
2020 General $27,128 103
2019 General $115,799 222

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Allen Morey
  • Urology median
  • Middle half of Urology
  • National median

In program year 2025, general payments to Allen Morey were reported at $211,651. Among 9,461 Urology profiles paid that year, the median was $629 and the middle half received between $190 and $1,620.

Show as a table
Year Allen Morey Urology median Middle half National median
2019 $115,799 $480 $147–$1,201 $163
2020 $27,128 $246 $87–$645 $114
2021 $89,824 $358 $111–$1,000 $132
2022 $111,304 $476 $143–$1,263 $149
2023 $140,373 $560 $168–$1,461 $160
2024 $217,748 $563 $170–$1,464 $164
2025 $211,651 $629 $190–$1,620 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Boston Scientific Corporation $681,289 1,002 payments
  2. Coloplast Corp $150,961 193 payments
  3. Laborie Medical Technologies Corp. $67,826 25 payments
  4. Endo USA, Inc. $12,196 13 payments
  5. Axonics Modulation Technologies, Inc. $389 6 payments
  6. Janssen Biotech, Inc. $173 2 payments
  7. Astellas Pharma US Inc $125 2 payments
  8. Myovant Sciences Inc. $118 1 payment
  9. Valencia Technologies Corporation $105 1 payment
  10. Antares Pharma, Inc. $100 2 payments
  11. Other $546 21 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $552,103 227 payments
  2. Consulting Fee $243,243 60 payments
  3. Travel and Lodging $64,931 147 payments
  4. Food and Beverage $34,068 825 payments
  5. Education $19,482 9 payments
Products named General payments · program years 2019–2025
  1. Titan Men's Health $133,629 147 payments
  2. General - Erectile Dysfunction $94,264 151 payments
  3. AdVance XP $72,539 54 payments
  4. AMS $58,159 59 payments
  5. AMS 700 CXR RTE KIT $56,407 25 payments
  6. TACTRA $38,387 16 payments
  7. Optilume Urethral Drug Coated Balloon $33,312 6 payments
  8. GENERAL THERAPIES $23,881 22 payments
  9. ADVANCE $20,937 9 payments
  10. TITAN Penile Reconstruction $16,767 33 payments
  11. Other $98,990 514 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Coloplast Corp $5,030 1 payment

Prescribing to Medicare patients

Part D · data year 2024 · 8 drugs

Part D claims

203

Median for Urology: 1,053

Drug cost

$40,624

Median for Urology: $101,464

Branded share of claims

32%

Median for Urology: 27.1%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Myrbetriq Mirabegron Brand 53 $33,805
Mirabegron Er Mirabegron Brand 12 $5,157
Tamsulosin Hcl Generic 44 $721
Finasteride Generic 37 $392
Oxybutynin Chloride Generic 14 $237
Levofloxacin Generic 14 $165
Ciprofloxacin Hcl Generic 13 $82
Meloxicam Generic 16 $65

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 10,221 Part D prescribers listed as Urology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 97 billing codes

Paid by Medicare

$148,308

Medicare's payments for the services billed

Medicare patients

329

Average age 74

Services billed

1,402

16 women, 313 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 51%
Cancer 49%
Ischemic heart disease 43%
Diabetes 35%
Chronic kidney disease 26%
Atrial fibrillation 22%
Depression 20%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

1,269 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Urology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record